Literature DB >> 32035944

Standard management options for rosacea: The 2019 update by the National Rosacea Society Expert Committee.

Diane Thiboutot1, Rox Anderson2, Fran Cook-Bolden3, Zoe Draelos4, Richard L Gallo5, Richard D Granstein6, Sewon Kang7, Marian Macsai8, Linda Stein Gold9, Jerry Tan10.   

Abstract

In 2017, a National Rosacea Society Expert Committee developed and published an updated classification of rosacea to reflect current insights into rosacea pathogenesis, pathophysiology, and management. These developments suggest that a multivariate disease process underlies the various clinical manifestations of the disorder. The new system is consequently based on phenotypes that link to this process, providing clear parameters for research and diagnosis as well as encouraging clinicians to assess and treat the disorder as it may occur in each individual. Meanwhile, a range of therapies has become available for rosacea, and their roles have been increasingly defined in clinical practice as the disorder has become more widely recognized. This update is intended to provide a comprehensive summary of management options, including expert evaluations, to serve as a guide for tailoring treatment and care on an individual basis to achieve optimal patient outcomes.
Copyright © 2020 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  drugs; erythema; flushing; lasers; lifestyle; management; ocular; papules; phenotypes; phymatous; pustules; rosacea; telangiectasia; therapy; utility

Year:  2020        PMID: 32035944     DOI: 10.1016/j.jaad.2020.01.077

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  12 in total

1.  Safety and Pharmacokinetics of FMX103 (1.5% Minocycline Topical Foam) in Subjects with Moderate-to-Severe Papulopustular Rosacea under Maximum-use Treatment Conditions.

Authors:  Terry M Jones; Iain Stuart
Journal:  J Clin Aesthet Dermatol       Date:  2021-03-01

2.  Effect and Safety of ALA-PDT Combined with 1550 nm Fractional Therapy Laser in Treating Rosacea.

Authors:  Hefei Wang; Xiaoxia An; Zhengli Wang
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-12       Impact factor: 2.650

3.  A Split-Face Study Assessing the Clinical Benefit, Tolerability and Subject Satisfaction of a Dermocosmetic in Subjects with Rosacea Associated with Erythema and Sensitive Skin.

Authors:  Enzo Berardesca; Adriana Bonfigli; Bernard Cribier; Frederic Flament; Marco Vicic; Delphine Kerob; Jerry Tan
Journal:  Clin Cosmet Investig Dermatol       Date:  2020-10-05

4.  Willingness-to-Pay and Benefit-Cost Analysis of IPL for Rosacea Treatment: A Cross-Sectional Study in China.

Authors:  Qing Deng; Shu-Ping Zhang; Yu-Xuan Deng; Fang-Fen Liu; Wei Shi; Hong-Fu Xie; Yi Xiao; Ying-Xue Huang; Ji Li
Journal:  Patient Prefer Adherence       Date:  2020-10-09       Impact factor: 2.711

5.  Rosacea: New Concepts in Classification and Treatment.

Authors:  Esther J van Zuuren; Bernd W M Arents; Mireille M D van der Linden; Sofieke Vermeulen; Zbys Fedorowicz; Jerry Tan
Journal:  Am J Clin Dermatol       Date:  2021-03-23       Impact factor: 7.403

6.  Metronidazole gel (0.75%) in Japanese patients with rosacea: A randomized, vehicle-controlled, phase 3 study.

Authors:  Yoshiki Miyachi; Kenshi Yamasaki; Tomomitsu Fujita; Chie Fujii
Journal:  J Dermatol       Date:  2021-12-01       Impact factor: 3.468

7.  Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis.

Authors:  Tamara Quint; Patrick M Brunner; Christoph Sinz; Irene Steiner; Robin Ristl; Kornelia Vigl; Susanne Kimeswenger; Katharina Neubauer; Detlev Pirkhammer; Martin Zikeli; Wolfram Hoetzenecker; Norbert Reider; Christine Bangert
Journal:  J Clin Med       Date:  2020-04-24       Impact factor: 4.241

8.  Bioinformatics and Network Pharmacology Identify the Therapeutic Role and Potential Mechanism of Melatonin in AD and Rosacea.

Authors:  Huaxiong Zhang; Yiya Zhang; Yangfan Li; Yaling Wang; Sha Yan; San Xu; Zhili Deng; Xinling Yang; Hongfu Xie; Ji Li
Journal:  Front Immunol       Date:  2021-11-23       Impact factor: 7.561

9.  Willingness-to-Pay and Benefit-Cost Analysis of Botulinum Toxin for the Treatment of Rosacea in China: Findings from a Web-Based Survey.

Authors:  Xizhao Yang; Yuyan Ouyang; Yuxuan Deng; Yi Xiao; Yan Tang; Dan Jian; Ji Li; Hongfu Xie; Yingxue Huang
Journal:  Patient Prefer Adherence       Date:  2021-06-03       Impact factor: 2.711

10.  Prevalence and Risk Factors of Anxiety and Depression in Rosacea Patients: A Cross-Sectional Study in China.

Authors:  Mengting Chen; Zhili Deng; Yingxue Huang; Ji Li
Journal:  Front Psychiatry       Date:  2021-06-16       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.